EyeGate Pharmaceuticals, a late-stage biotech developing a treatment for eye inflammation, postponed its IPO on Thursday. It had planned to raise $25 million on Thursday night at a fully diluted market cap of $101 million by offering 2.0 million shares at a range of $12 to $14 per share, where insiders would purchase 10% of the IPO. The recent selloff in growth stocks may have been a deciding factor.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
